Smokescreen Studies

The following studies use the Smokescreen chip.

Study 31 – Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT); CTN-0051

Ancillary Study: Contribution of Specified Opioid Receptor Gene Variants to Outcome of Extended Release Naltrexone vs. Buprenorphine/Naloxone Treatment for Opioid Dependence Investigators:  John Rotrosen, M.D. (NYU Langone Medical Center); Ancillary Study: Mary Jeanne Kreek, M.D. (Rockefeller University) Status:  Available at dbGaP dbGaP Accession ID:  phs002876.v1.p1 Abstract:  For opioid-dependent patients in the U.S. and most of the rest of the world,...

Read more ...

Study 51 – Genotyping on Smokescreen Microarray Chip

Investigators:  Jasmin Vassileva and Alexandre Todorov Release Date:  Sites 500 & 518: 12/16/2021; Site 501: 06/28/2019 dbGaP Accession IDs: phs001647.v1.p1; phs001804.v1.p1 Files Instrument References

Read more ...

Study 52 – Genetic Contribution to the Abuse Liability of Oxycodone

Investigator:  Jermaine Jones Release Date:  08/23/2018 dbGaP Accession ID:  phs001559.v1.p1 Files Instrument References

Read more ...

Study 53 – The Women’s Interagency HIV Study (WIHS)

Investigator:  Brad Aouizerat Release Date:  05/14/2018 dbGaP Accession ID:  phs001503.v1.p1 Files Instrument References

Read more ...

Study 54 – Genotyping on Smokescreen Microarray Chip

Investigator:  Deborah Mash Release Date:  10/12/2017 dbGaP Accession ID:  phs001377.v1.p1 Files Instrument References

Read more ...

Study 55 – ALIVE Cohort Smokescreen GWAS

Investigator:  Brion Maher Release Date:  03/14/2018 dbGaP Accession ID:  phs001494.v1.p1 Files Instrument References

Read more ...

Study 56 – Assess the Cardiovascular, Cognitive, and Subjective Effects of Atomoxetine in Combination with IV Methamphetamine

Investigator:  Edythe D. London Release Date:  03/29/2018 dbGaP Accession ID:  phs001195.v1.p1 Files Instrument References

Read more ...

Study 57 – Neural Systems, Inhibitory Control, and Methamphetamine Dependence

Investigator:  Edythe D. London Release Date:  05/01/2018 dbGaP Accession ID:  phs001197.v1.p1 Files Instrument References

Read more ...

Study 58 – Early Methamphetamine Abstinence fMRI and Brain Function

Investigator:  Edythe D. London Release Date:  06/01/2018 dbGaP Accession ID:  phs001198.v1.p1 Files Instrument References

Read more ...

Study 59 – Smokescreen; Opioid/Cocaine Use; Antisocial Drug Dependence

Investigator:  Robin Corley Release Date:  06/03/2021 dbGaP Accession ID:  phs001841.v1.p1 Files Instrument References

Read more ...

Study 60 – Gene-Environment Interactions in COCCaINE Use Disorder: Collaborative Case-Control Initiative in Cocaine Addiction

Investigator:  Rodrigo Grassi-Oliveira Release Date:  08/01/2019 dbGaP Accession ID:  phs001810.v1.p1 Files Instrument References

Read more ...

Study 61 – Smokescreen; NJD/NID cohort

Investigator:  Stanley Weiss Release Date:  07/26/2022 dbGaP Accession ID:  phs002140.v1.p1 Files Instrument References

Read more ...

Study 62 – Prevention of Viral Hepatitis and HIV in Drug Users – A Hepatitis B Model for HIV and an HB Vaccine Model (DASH)

Investigator:  Lu-Yu Hwang Release Date:  06/03/2021 dbGaP Accession ID:  phs002331.v1.p1 Files Instrument References Contributing PIs:  Lu-Yu Hwang dbGaP Accession:  phs002331 Study Alias:  Smokescreen; DASH

Read more ...

Study 63 – Smokescreen; InC3 cohort substance abusers

Investigator:  Kimberly Page Release Date:  05/18/2021 dbGaP Accession ID:  phs002310.v1.p1 Files Instrument References

Read more ...

Study 64 – Smokescreen; Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS)

Investigator:  Inga Peter Release Date:  01/21/2020 dbGaP Accession ID:  phs001788.v1.p1 Files Instrument References

Read more ...

Study 65 – Spit for Science™

Investigator:  Danielle Dick Release Date:  6/6/2019 dbGaP Accession ID:  phs001754.v1.p1 Spit for Science™ Overview: Spit for Science™ is a university-wide research opportunity with the scientific goal of understanding how genetic and environmental factors come together to influence substance use and emotional health across the college years and beyond. To address this goal, we have comprehensively and longitudinally studied eligible incoming freshmen (18 years or older) from a diverse...

Read more ...